OsteoarthritisNCT07566520
Prevalence of Sarcopenia and Its Associated Factors in Patients With Knee Osteoarthritis in a Tertiary Care Hospital in Upper Egypt
An observational study of Osteoarthritis and Sarcopenia, run by Assiut University at 1 site in Egypt.
Trial summary
Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general… Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Osteoarthritis, Sarcopenia
- How many people
- 224 participants
- Where
- 1 siteEgypt
- Study dates
- May 2026to Jul 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients aged 40 years and older, diagnosed with knee osteoarthritis, who are attending the Assiut University Trauma Hospital.
Who may be able to join
- Adults aged 40 years and older diagnosed with knee OA based on the American College of Rheumatology (ACR) criteria.
- Patients who are willing to participate and provide informed written consent.Exclusion Criteria:
- Inflammatory arthritis: patients with rheumatoid arthritis, gouty arthritis, or systemic lupus erythematosus (SLE) to avoid confusion with inflammatory muscle wasting.
- Physical Limitations: amputees or those with severe physical deformities preventing gait speed tests or handgrip measurement.
- Patients with cardiac pacemakers or implanted electronic devices (as these interfere with Bioelectrical Impedance Analysis (BIA)).
- Severe Comorbidities: end-stage renal or hepatic disease, advanced malignancy or cachexia.
- Severe neurological disorders (e.g., Parkinson's disease, Stroke with paralysis) that directly affect muscle mass and mobility.
- Prolonged use of systemic corticosteroids (which cause secondary sarcopenia)
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Assiut University Trauma Hospital
Asyut
Esraa M.H Ibrahim, +201112969235, esraa.m.hosny@aun.edu.eg
About this study
Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general population.
Read the detailed description
Chronic inflammation, joint pain, and reduced physical activity in OA patients create a vicious cycle that accelerates muscle mass loss and functional decline. While international data is robust, Egyptian epidemiological data remains limited. Recent studies in Egypt have identified a high risk of sarcopenia among older adults with fragility fractures and a prevalence of 17.7% in nursing home residents. However, targeted data on the OA population in Egypt is still lacking. Current management in Egyptian primary care centers primarily focuses on symptomatic relief of OA through analgesics and physical therapy. Sarcopenia often remains underdiagnosed because routine screening tools, such as the SARC-F questionnaire or Bioelectrical Impedance Analysis (BIA), are not yet integrated into standard family medicine protocols. This oversight leads to increased frailty and poorer surgical outcomes for patients requiring joint replacement. In the family medicine practice, identifying sarcopenia early is vital for holistic care. Understanding the local prevalence and risk factors-such as Vitamin D deficiency, sedentary behavior, and low protein intake-is essential to tailor interventions. This research aims to provide the evidentiary basis for incorporating sarcopenia screening into primary care OA management, ultimately improving patient mobility and quality of life
- Conditions
- Osteoarthritis, Sarcopenia
- Medical subject headings
- Osteoarthritis, Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Knee Osteoarthritis Patients | Adults aged 40 years and older diagnosed with knee osteoarthritis based on the American College of Rheumatology (ACR) criteria attending the Assiut University Trauma Hospital. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of sarcopenia in knee osteoarthritis patients
Prevalence of OA patients who meet the diagnostic criteria for sarcopenia (low muscle mass, strength, and physical performance) according to the European Working Group on Sarcopenia in Older People (EWGSOP2) revised consensus.
Measured: at baseline
Secondary outcomes (2)
Nutritional Risk Assessment via Malnutrition Universal Screening Tool (MUST)
Evaluation of nutritional status as a factor associated with sarcopenia. The MUST score is a five-step screening tool with a total score ranging from 0 (low risk) to 2 or more (high risk).
Measured: Baseline
The Quality of Life Factor (EQ-5D Index)
Assessment of the impact of sarcopenia and OA on quality of life. The 5 dimensions (Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression)
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2026
- Study startMay 2026 (estimated)
- Primary completionApr 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 224 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Esraa Mostafa Hosny Ibrahim, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07566520
- Sponsor's protocol ID
- Sarcopenia_OA_Assiut
- Status last verified
- Apr 2026
- First submitted
- 15 Apr 2026
- Last updated
- 5 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Sarcopenia and Its Associated Factors in Patients With Knee Osteoarthritis in a Tertiary Care Hospital in Upper Egypt
- ClinicalTrials.gov ID
- NCT07566520
- Acronym / sponsor ID
- Sarcopenia_OA_Assiut
- Conditions
- Osteoarthritis, Sarcopenia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 224 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- May 2026 (estimated)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 5 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general population.
Detailed description
Chronic inflammation, joint pain, and reduced physical activity in OA patients create a vicious cycle that accelerates muscle mass loss and functional decline. While international data is robust, Egyptian epidemiological data remains limited. Recent studies in Egypt have identified a high risk of sarcopenia among older adults with fragility fractures and a prevalence of 17.7% in nursing home residents. However, targeted data on the OA population in Egypt is still lacking. Current management in Egyptian primary care centers primarily focuses on symptomatic relief of OA through analgesics and physical therapy. Sarcopenia often remains underdiagnosed because routine screening tools, such as the SARC-F questionnaire or Bioelectrical Impedance Analysis (BIA), are not yet integrated into standard family medicine protocols. This oversight leads to increased frailty and poorer surgical outcomes for patients requiring joint replacement. In the family medicine practice, identifying sarcopenia early is vital for holistic care. Understanding the local prevalence and risk factors-such as Vitamin D deficiency, sedentary behavior, and low protein intake-is essential to tailor interventions. This research aims to provide the evidentiary basis for incorporating sarcopenia screening into primary care OA management, ultimately improving patient mobility and quality of life
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Knee Osteoarthritis Patients | – | –Adults aged 40 years and older diagnosed with knee osteoarthritis based on the American College of Rheumatology (ACR) criteria attending the Assiut University Trauma Hospital. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients aged 40 years and older, diagnosed with knee osteoarthritis, who are attending the Assiut University Trauma Hospital.
Key inclusion criteria (8 listed)
- Adults aged 40 years and older diagnosed with knee OA based on the American College of Rheumatology (ACR) criteria.
- Patients who are willing to participate and provide informed written consent.Exclusion Criteria:
- Inflammatory arthritis: patients with rheumatoid arthritis, gouty arthritis, or systemic lupus erythematosus (SLE) to avoid confusion with inflammatory muscle wasting.
- Physical Limitations: amputees or those with severe physical deformities preventing gait speed tests or handgrip measurement.
- Patients with cardiac pacemakers or implanted electronic devices (as these interfere with Bioelectrical Impedance Analysis (BIA)).
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of sarcopenia in knee osteoarthritis patients
Time frame: at baseline
Prevalence of OA patients who meet the diagnostic criteria for sarcopenia (low muscle mass, strength, and physical performance) according to the European Working Group on Sarcopenia in Older People (EWGSOP2) revised consensus.
2 secondary outcomes
Nutritional Risk Assessment via Malnutrition Universal Screening Tool (MUST)
Time frame: Baseline
The Quality of Life Factor (EQ-5D Index)
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Osteoarthritis and Sarcopenia, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Esraa M.H Ibrahim (+201112969235, esraa.m.hosny@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of sarcopenia in knee osteoarthritis patients (time frame: at baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.